17.44USD+10.24%Mkt Cap: 636.09M USDP/E: —Last update: 2026-06-01
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap636.09M USD
Enterprise Value270.43M USD
Revenue (TTM)—
Gross Profit-139.61M USD
Net Income (TTM)-163.71M USD
Revenue/Share—
Last Price17.44 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.03
PEG—
EV/EBITDA-1.50
EV/Revenue—
P/S—
P/B2.16
EPS (TTM)-4.71
EPS (Forward)-3.18
52W Range
14.7922% of range26.80
52W High26.80 USD
52W Low14.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-41.80%
ROA-37.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-125.81M USD
CapEx (TTM)358.00K USD
FCF Margin—
FCF Yield—
Net Debt-286.46M USD
Net Debt/EBITDA1.59
Balance Sheet
Debt/Equity0.04
Current Ratio8.74
Quick Ratio8.65
Book Value/Sh7.379 USD
Cash/Share8.210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)39.29 USD
Target Range30.00 USD – 54.00 USD
# Analysts7
Ownership
Shares Out.34.89M
Float31.08M
Insiders6.51%
Institutions42.71%
Short Interest
Short Ratio12.6d
Short % Out.11.22%
Shares Short4.03M
Technical
SMA 5019.68 (-11.4%)
SMA 20019.68 (-11.4%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)489.87K
Avg Vol (10d)357.02K
Technical Indicators
RSI (14)40.9
MACD-1.1138
MACD Signal-0.9342
MACD Hist.-0.1796
BB Upper21.80 USD
BB Middle18.05 USD
BB Lower14.29 USD
BB Width41.61%
ATR (14)2.087 USD
Vol Ratio (20d)0.49x